5-iodo-3-methyl-1-phenylpyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-iodo-3-methyl-1-phenylpyrazole
• 英文别名: 5-iodo-3-methyl-1-phenyl-1H-pyrazole；5-Jod-3-methyl-1-phenyl-1H-pyrazol；5-iodo-3-methyl-1-phenyl-1H-pyrazole
• 化学式: C₁₀H₉IN₂
• 分子量: 284.099
• InChiKey: YGLNPVUBHMKAEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-甲基-1-苯基吡唑 在 四甲基乙二胺 、 lithium diisopropyl amide 、 三丁基氯化锡 、 碘 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.0h， 以1.02 g的产率得到5-iodo-3-methyl-1-phenylpyrazole
  参考文献：
  名称：

  Synthesis and Reactions of Silylated and Stannylated 1,2-Azoles

  摘要：

  硅或锡4-金属化吡唑和异恶唑是通过硅烷或锡烷锡化作用从4-卤代恶唑合成的。另一方面，5-金属化吡唑是通过5-未取代吡唑与LDA反应，随后用氯硅烷和氯锡烷处理制备的。此外，从5-未取代的4-卤代吡唑出发，并应用这两种方法，得到了具有不同于三甲基硅基或三丁基锡基的不同硅基的4,5-二金属化吡唑。还研究了一些区域选择性原位取代反应。

  DOI：

  10.1055/s-2001-17699

文献信息

• Modulators of proteolysis and associated methods of use
  申请人：Arvinas Operations, Inc.

  公开号：US11161841B2

  公开（公告）日：2021-11-02

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，它们可用作 Kirsten 大鼠肉瘤蛋白（靶蛋白）的调节剂。特别是，本公开涉及双功能化合物，其一端含有与相应 E3 泛素连接酶结合的 Von Hippel-Lindau、cereblon、Apotosis Proteins 抑制剂或小鼠双敏同源物 2 配体，另一端含有与靶蛋白结合的分子，从而使靶蛋白靠近泛素连接酶以实现对靶蛋白的降解（和抑制）。本公开物具有与降解/抑制靶蛋白相关的广泛药理活性。本公开的化合物和组合物可以治疗或预防因目标蛋白的聚集、积累和/或过度激活而导致的疾病或失调。
• Michaelis; Voss; Greiss, Chemische Berichte, 1901, vol. 34, p. 1301
  作者：Michaelis、Voss、Greiss

  DOI：——

  日期：——
• Michaelis; Pasternack, Chemische Berichte, 1899, vol. 32, p. 2406
  作者：Michaelis、Pasternack

  DOI：——

  日期：——
• MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190315732A1

  公开（公告）日：2019-10-17

  The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
• MODULATORS OF FAK PROTEOLYSIS AND ASSOCIATED METHODS OF USE
  申请人：ARVINAS OPERATIONS, INC.

  公开号：US20200038513A1

  公开（公告）日：2020-02-06

  The present disclosure relates to bifunctional compounds, which find utility as modulators of focal adhesion kinase (FAK) or protein tyrosine kinase 2 (PTK2). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.